Dependence on RAD52 and RAD1 for anticancer drug resistance mediated by inactivation of mismatch repair genes
Open Access
- 1 January 1999
- journal article
- research article
- Published by Elsevier in Current Biology
- Vol. 9 (1) , 51-54
- https://doi.org/10.1016/s0960-9822(99)80047-5
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- hMLH1 expression and cellular responses of ovarian tumour cells to treatment with cytotoxic anticancer agentsOncogene, 1997
- Mlh1 is unique among mismatch repair proteins in its ability to promote crossing-over during meiosis.Genes & Development, 1997
- Differential human nucleotide excision repair of paired and mispaired cisplatin-DNA adductsNucleic Acids Research, 1997
- Biochemistry and genetics of eukaryotic mismatch repair.Genes & Development, 1996
- The HMG-domain protein Ixr1 blocks excision repair of cisplatin-DNA adducts in yeastMutation Research/DNA Repair, 1996
- Cisplatin and DNA repair in cancer chemotherapyTrends in Biochemical Sciences, 1995
- Role of the Rad1 and Rad10 Proteins in Nucleotide Excision Repair and RecombinationJournal of Biological Chemistry, 1995
- Removal of Nonhomologous DNA Ends in Double-Strand Break Recombination: the Role of the Yeast Ultraviolet Repair Gene RAD1Science, 1992
- Isolation and characterization of yeast DNA repair genesCurrent Genetics, 1983
- The distribution of the numbers of mutants in bacterial populationsJournal of Genetics, 1949